Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, ...
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel ...
BEIJING, Sept 24 (Reuters) - China's Sinovac Biotech expects to begin analysing final-stage human trial data on its coronavirus vaccine candidate this year to decide whether it is effective enough to ...
Sinovac Biotech Ltd. (NASDAQ: SVA) (“ SINOVAC ” or the “ Company ”), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Court’s interlocutory order ...
Board continues to govern Company and remains committed to its mission of restoring fairness, delivering value, and protecting the rights of all valid shareholders Paying Agent has begun distributing ...
PALO ALTO, Calif.--(BUSINESS WIRE)-- Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and a long term shareholder of Sinovac Biotech ...
Sinovac Biotech and several of its executives and directors were hit with a securities class action on April 17 in Delaware Court of Chancery. The suit, brought by Pomerantz LLP and Ashby & Geddes, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results